The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 18, 2018

Filed:

Mar. 14, 2018
Applicant:

Pharmabcine Inc., Daejeon, KR;

Inventors:

Joong Kyu Kim, Daejeon, KR;

Jin San Yoo, Daejeon, KR;

Sang Hoon Lee, Palo Alto, CA (US);

Weon Sup Lee, Daejeon, KR;

Sung Woo Kim, Daejeon, KR;

Sang Ryeol Shim, Daejeon, KR;

Jin Sang Yoo, Daejeon, KR;

Young Ae Lee, Daejeon, KR;

Mi Ju Park, Daejeon, KR;

Sang Soon Byun, Daejeon, KR;

Hyuk Joon Lee, Daejeon, KR;

Do Yun Kim, Chungcheongbuk-do, KR;

Yeun Ju Kim, Daejeon, KR;

Jin Hee Choi, Daejeon, KR;

Kyung Hee Nahm, Daejeon, KR;

Ju Ryung Nam, Daejeon, KR;

Jong Geun Jeong, Daejeon, KR;

Bo Young Jeong, Daejeon, KR;

Eun Jin Lee, Daejeon, KR;

Seon Young Lee, Seoul, KR;

In Sook Park, Daejeon, KR;

Jin Sook Lee, Daejeon, KR;

Jae Bong Yoon, Daejeon, KR;

Nam Ye Kim, Daejeon, KR;

Seon Hwan Oh, Daejeon, KR;

Assignee:

PharmAbcine Inc., Daejeon, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 14/705 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); C07K 14/705 (2013.01); C07K 16/28 (2013.01); G01N 33/5023 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01); G01N 2333/705 (2013.01);
Abstract

The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.


Find Patent Forward Citations

Loading…